Anemia is associated with various hematologic diseases that can have a significant impact on patient outcomes and quality of life. Lower-risk myelodysplastic syndromes (MDS) and myeloproliferative neoplasm (MPN) primary myelofibrosis (MF) are associated with defective red blood cell (RBC) development and differentiation. This is often treated with erythroid stimulating agents (ESAs); however, over time, resistance to currently available ESAs develops, leading to RBC transfusions and iron overload, poor quality of life, and shortened survival. Patients with β-thalassemia, one of the most common genetic diseases in the world, have defective hemoglobin production and are also often impacted by dependence on blood transfusions. Luspatercept is a first-in-class erythroid maturation agent that targets TGF-β; it was recently approved to treat the anemia associated with these disorders and promises a new era in management of disease-related anemia. In this interactive eCourse, 2 experts in malignant hematology present key evidence in support of novel treatments to manage hematologic-disease related anemia and discuss patient cases and the most recent clinical trial data to illustrate best practices for managing hematologic disease-related anemia in patients with MDS, MPNs MF, and β-thalassemia.
Interactive, audio-enhanced slide lecture
After completing this activity, participants should be better able to:
- Review evidence for novel targets for treatment of anemia associated with MDS, MPN, or β-thalassemia
- Identify novel therapies for the treatment of anemia in hematologic disorders
- Utilize recommended strategies to manage side effects of novel therapies for anemia associated with MDS, MPN, or β-thalassemia
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit.
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until April 25, 2022. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from Bristol-Myers Squibb Company.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Kleinert: consulting: Acceleron, Chiesi, Celgene; non-CE/CME services: GBT, Novartis.
Ms Lyle: consulting: AbbVie, Agios, Bristol-Myers Squibb, Incyte Corporation.
None of the members of the PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: April 26, 2021
Expiration date: April 25, 2022
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 101621B